What Researchers Did
Researchers reviewed the current literature on various inhaled therapeutics for migraine treatment, including drugs like dihydroergotamine mesylate and prochlorperazine, as well as oxygen and nitrous oxide therapies.
What They Found
In phase 3 studies, inhaled dihydroergotamine mesylate (MAP0004) demonstrated promising efficacy for acute migraine with a favorable tolerability profile. In phase 2 trials, inhaled prochlorperazine showed good pharmacokinetics and efficacy, while inhaled loxapine did not yield encouraging results. The authors suggest that dihydroergotamine mesylate has potential for clinical use pending regulatory approval.
What This Means for Canadian Patients
Canadian patients suffering from migraine may eventually benefit from new inhaled treatment options that could offer rapid relief and improved tolerability. These therapies could provide alternatives for those who do not respond well to current oral or injectable medications.
Canadian Relevance
This review article does not have a direct Canadian connection.
Study Limitations
As a review article, this study synthesizes existing literature and does not present new primary research data.